Drug Profile
Glutamine - Emmaus Medical
Alternative Names: ELS-001; ELS-004; ELS-007; Endari; L-glutamine - Emmaus Medical; L-glutamine oral powder - Emmaus Medical; Levoglutamide; NutreStore; PGLG - Emmaus Medical; SCD therapy; XyndariLatest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Nutritional Restart Pharmaceutical
- Developer Emmaus Medical; myTomorrows; Nutritional Restart Pharmaceutical
- Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Basic amino acids; Diamino amino acids; Neutral amino acids; Small molecules
- Mechanism of Action Antioxidants; Protein synthesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diverticulitis; Sickle cell anaemia
Highest Development Phases
- Marketed Short bowel syndrome; Sickle cell anaemia
- Phase III Thalassaemia
- Phase II Diverticulitis
- Phase I Pancreatic cancer
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 02 Feb 2024 Registered for Sickle cell anaemia (In adults, In children, In adolescents) in Puerto Rico (PO)
- 13 Jul 2023 Emmaus Life Sciences plans to launch L-glutamine in Oman
- 31 May 2023 Emmaus Life Sciences plans to launch Glutamine (Endari®) for Sickle cell anaemia in the Middle East, North Africa region and India